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Introduction: Metformin has anti-inflammatory and anti-thrombotic effects that may improve the outcome of
critical illness, but clinical data are limited. We examined the impact of preadmission metformin use on mortality
among intensive care unit (ICU) patients with type 2 diabetes.
Methods: We conducted this population-based cohort study among all persons admitted to the 17 ICUs in
Northern Denmark (population approximately 1.8 million). We focused on all patients with type 2 diabetes who
were admitted to the ICUs between January 2005 and December 2011. Through individual-level linkage of
population-based medical databases, type 2 diabetes was identified using a previously validated algorithm
including hospital diagnoses, filled prescriptions for anti-diabetic drugs, and elevated HbA1c levels. Metformin use
was identified by filled prescriptions within 90 days before admission. Covariates included surgery, preadmission
morbidity, diabetes duration, and concurrent drug use. We computed 30-day mortality and hazard ratios (HRs) of
death using Cox regression adjusted for covariates, both overall and after propensity score matching.
Results: We included 7,404 adult type 2 diabetes patients, representing 14.0% of 52,964 adult patients admitted to
the ICUs. Among type 2 diabetes patients, 1,073 (14.5%) filled a prescription for metformin as monotherapy within
90 days before admission and 1,335 (18.0%) received metformin in combination with other anti-diabetic drugs.
Thirty-day mortality was 17.6% among metformin monotherapy users, 17.9% among metformin combination
therapy users, and 25.0% among metformin non-users. The adjusted HRs were 0.80 (95% confidence interval (CI):
0.69, 0.94) for metformin monotherapy users and 0.83 (95% CI: 0.71, 0.95) for metformin combination therapy users,
compared to non-users. Propensity-score-matched analyses yielded the same results. The association was evident
across most subgroups of medical and surgical ICU patients, but most pronounced in elderly patients and in
patients with well-controlled diabetes. Former metformin use was not associated with decreased mortality.
Conclusions: Preadmission metformin use was associated with reduced 30-day mortality among medical and
surgical intensive care patients with type 2 diabetes.Introduction
Metformin is a widely used drug for treatment of type
2 diabetes [1-3] and may reduce all-cause mortality
and cardiovascular event rates compared with other
anti-diabetic drugs [4-6]. Beside its glucose-lowering
effects [7], metformin has pleiotropic effects [8] that may* Correspondence: cc@dce.au.dk
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distribution, and reproduction in any mediumbe beneficial during critical illness. Experimental animal
studies found that metformin has anti-inflammatory and
anti-thrombotic effects that may influence the outcome
of critical illness by attenuating the development and
progression of acute organ dysfunction, including acute
lung injury [9-11].
Only a few human studies have examined the effect of
metformin in relation to critical illness. An Iranian clinical
trial of 21 ICU patients detected a potentially decreased
level of inflammatory cytokines when metformin was
added to intensive insulin therapy [12]. In a US cohort ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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preadmission metformin use was associated with a
more than 50% decreased postoperative morbidity rate,
including infections, and with a substantial decrease in
inpatient mortality [13]. However, metformin may not
affect mortality in patients with acute myocardial infarction
[14-16], and any potential impact may be limited to
conditions with severe inflammation [17,18]. As yet, no
data exist on the impact of metformin on mortality after
admission to an ICU.
Examination of the association between preadmission
metformin use and mortality following ICU admission may
improve understanding of disease processes and identify
future therapeutic targets. We therefore examined whether
preadmission metformin use was associated with decreased
30-day mortality among ICU patients with type 2 diabetes.Materials and methods
We conducted this cohort study among adults with type
2 diabetes who were admitted to an ICU in Northern
Denmark (population approximately 1.8 million) be-
tween 1 January 2005 and 31 December 2011 [19]. We
required that study participants had lived in the area for
at least two years, in order to ensure availability of a
complete history of laboratory and prescription data. Data
collection was based on unambiguous individual-level
linkage between population-based medical registries and
databases using the unique Danish Civil Registration
number assigned to each Danish citizen at birth or upon
immigration [20,21]. Denmark provides tax-financed health
care, with partial reimbursement of drugs, including anti-
diabetic drugs, for all Danish inhabitants [22]. Northern
Denmark has seventeen ICUs, including eight units in uni-
versity hospitals and nine multidisciplinary units in re-
gional hospitals. The Danish Data Protection Agency
approved the study (Record No. 2009-41-3987).
According to Danish law, informed consent is not re-
quired for non-interventional studies based on routinely
collected data.Intensive care patients with type 2 diabetes
We used the Danish National Registry of Patients (DNRP)
to identify adults (15 years of age or older) admitted to an
ICU during the study period (n = 52,964) [19]. The DNRP
contains data on virtually all admissions to Danish hospitals
since 1977 and on outpatient clinic visits since 1995 [23].
Data include civil registration number, dates of hospital
admission and discharge, one primary diagnosis (main
reason for hospitalization), up to nineteen secondary
diagnoses, surgical procedures, and major treatments.
Diagnoses are coded according to the International
Classification of Diseases, 8th edition (ICD-8) until 1993
and 10th edition (ICD-10) thereafter. Administration ofintensive care therapy has been coded accurately since
2005 [24,25]. The DNRP is used as the data source for the
Danish Intensive Care Database (a nationwide database for
quality monitoring), which implies mandatory reporting
and regular validation of data.
We identified type 2 diabetes using an algorithm with
high validity, incorporating any previous inpatient or
outpatient clinic diagnosis of diabetes after age 30 years,
a diabetes diagnosis before age 30 years with no insulin
prescriptions within a year before ICU admission, any
filled prescription for an oral anti-diabetic drug since 1998,
or a glycosylated hemoglobin A1c (HbA1c) level of 6.5% or
more at the last measurement within a year before admis-
sion [19,26]. Patients with polycystic ovarian syndrome
treated with metformin and no diagnosis of diabetes were
excluded (n = 19) [15]. Relevant diagnostic, laboratory, and
drug codes are provided in Additional file 1.
Prescription data were obtained from the Aarhus
University Prescription Database, which contains data
on all filled prescriptions in the study area since 1998.
Data include date of dispensing, type of drug according
to the anatomical therapeutic chemical (ATC) classifica-
tion system, and total amount dispensed [27]. Data on
HbA1c levels and other laboratory measurements were
obtained from the clinical laboratory information system
database, which includes results of blood tests performed
at hospitals, outpatient clinics, and general practitioners
[28].Preadmission metformin use
For each patient, we identified all prescriptions for anti-
diabetic drugs, including metformin [see Additional file
1 for ATC codes]. Patients defined as current metformin
users had a filled prescription within 90 days before
admission; other ICU patients were defined as non-users
[29]. The 90-day period was chosen because prescriptions
rarely are issued for more than three months [29]. In
additional analyses, we divided current users into new
and long-term users [30] and considered recent (last
prescription filled 91 to 365 days before ICU admission)
and former use of metformin (last prescription filled 1 to
5 years before ICU admission). We included data on
in-hospital administration of metformin from the day
of hospital admission through the day of ICU admission,
using an electronic in-hospital medication database that
was implemented during the study period and available
for a subset of the study population.Mortality
We followed patients, using the Danish Civil Registration
System (DCRS), to the date of death or emigration. DCRS
includes complete data on vital status, residence, and mari-
tal status for all Danish inhabitants, updated daily [20].
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Because any effect of metformin may be mediated through
decreasing severity of organ dysfunction, we assessed acute
organ dysfunction on the day of ICU admission using the
laboratory cutoff values in the Sequential Organ Failure
Assessment (SOFA) score criteria for kidney, liver, and
coagulation system dysfunction [31]. We identified acute
organ dysfunction using the laboratory database, which
included a creatinine measurement on the day of ICU
admission for 5,474 (73.9%) of the patients [28]. We did
not include urine output to assess kidney dysfunction. For
patients without a routine measurement on the day of
ICU admission, we computed the mean of the values the
day before and the day after this admission [31]. We also
obtained data on C-reactive protein (CRP), as a marker of
inflammation, and data from the DNRP on any organ
supportive treatment with mechanical ventilation, renal
replacement therapy, and inotropes/vasopressors.
Potential confounders and other covariates
We used the DCRS to obtain demographic data on age,
sex, and marital status as a marker of social status. We
retrieved data from the DNRP on relevant inpatient and
outpatient hospital contacts with a diagnosis of important
preadmission chronic diseases within five years before the
current admission [32]. See Additional file 1 for ICD-10
codes.
Because cardiovascular drug use may affect prognosis
following intensive care, we obtained information from
the prescription database on prescriptions for low-dose
aspirin within 90 days, beta-blockers within 120 days, or
statins within 120 days before ICU admission. These time
periods reflect typical prescription durations [33-35].
In order to study possible differential impacts of
metformin use in subgroups of ICU patients, we obtained
data from the DNRP on diagnostic categories defined by
the primary diagnosis during the current hospitalization.
We defined ICU admission type as medical, acute cardiac
surgical, acute non-cardiac surgical, elective cardiac
surgical, and elective non-cardiac surgical according
to hospital admission type and surgical procedures
performed on the day of ICU admission or within seven
days beforehand [36,37].
Statistical analyses
We used contingency tables to describe covariates and
rates of organ dysfunction. We followed patients from
date of ICU admission until date of death, emigration, or
for up to 30 days, whichever occurred first. Thirty-day
mortality was assessed as one minus the Kaplan-Meier
estimator. We used Cox proportional hazards regression
analysis to compute hazard ratios (HRs) for death adjusted
for the potential confounders in Table 1 (age, sex, maritalstatus, preadmission morbidity, concurrent drug use,
diabetes duration, and last HbA1c measurement within
a year before the current admission). In an additional
analysis we adjusted for organ dysfunction, although this
variable may be in the causal pathway [38]. Furthermore,
we compared current (new and long-term), recent, and
former metformin users with never-users.
We also compared metformin monotherapy users with
sulfonylurea monotherapy users because they may have
comparable severity of diabetes. We extended the exposure
window from 90 to 180 and to 365 days to assess the
sensitivity of the cut point. In addition, for the subset of
patients with available in-hospital medication data, we
described the proportion of patients continuing metformin
use between hospital admission and ICU admission.
We also conducted analyses using propensity-score ad-
justment and matching, because these may be more robust
when there are few outcomes per covariate [39,40]. The
propensity score is the probability of being a metformin
user. We estimated the propensity score for each study
participant using a multivariate logistic regression model
including all variables in Table 1. We adjusted for the pro-
pensity score in the Cox regression, both in an overall ana-
lysis and stratified by potential confounders, diagnostic
category, admission type, and by continuation/discontinu-
ation of metformin between hospital and ICU admission.
Finally, we carried out propensity-score matching of
metformin users with non-users, which was possible in
2,192 (91.0%) patients within a range of ± 0.025. Covariates
included in the estimation of the propensity score were
adequately balanced after matching [41]. For the propensity-
score matched analysis, we used stratified Cox regression
to account for matching [42].
All analyses were conducted using the Stata software
package, version 10.1. (StataCorp, College Station, TX, USA)
Results
The study included 7,404 patients with adult type 2
diabetes, corresponding to 14.0% of 52,964 adult patients
admitted to the ICUs in the study area. Among type 2
diabetes patients, 1,073 (14.5%) were metformin monother-
apy users, 1,335 (18.0%) used metformin in combination
with other anti-diabetic drugs, and 4,996 (67.5%) were
non-users.
Descriptive data are presented in Tables 1 and 2. A
larger proportion of metformin monotherapy and com-
bination therapy users were under age 80 years, compared
with non-users. Both groups of metformin users also had
lower preadmission morbidity than non-users, including
those with cardiovascular, liver, renal, and chronic pul-
monary diseases. Diabetic nephropathy and retinopathy
were more common in metformin combination therapy
users and in non-users than in metformin monotherapy
users. Long diabetes duration (5 years or more) and high
Table 1 Characteristics of metformin users and non-users (overall and after propensity score-matching)
Full cohort of all ICU patients with type 2
diabetes (n = 7,404)
Propensity score-matched
cohort
All Metformin users All Metformin













(n = 1,073), n (%)
Metformin combination
therapy users
(n = 1,335), n (%)
Age group, years
15 to 39 23 (2.1) 21 (1.6) 44 (1.8) 141 (2.8) 43 (2.0) 42 (1.9)
40 to 59 184 (17.1) 241 (18.1) 425 (17.7) 854 (17.1) 389 (17.8) 352 (16.1)
60 to 79 731 (68.1) 939 (70.3) 1,670 (69.4) 2,965 (59.3) 1,491 (68.0) 1,505 (68.7)
80+ 135 (12.6) 134 (10.0) 269 (11.2) 1,036 (20.7) 269 (12.3) 293 (13.4)
Sex
Female 420 (39.1) 499 (37.4) 919 (38.2) 2,085 (41.7) 867 (39.6) 835 (38.1)
Male 653 (60.9) 836 (62.6) 1,489 (61.8) 2,911 (58.3) 1,325 (60.5) 1,357 (61.9)
Marital status
Married 593 (55.3) 749 (56.1) 1,342 (55.7) 2,418 (48.4) 1,183 (54.0) 1,173 (53.5)
Never married 112 (10.4) 157 (11.8) 269 (11.2) 573 (11.5) 246 (11.2) 243 (11.1)
Divorced 154 (14.4) 179 (13.4) 333 (13.8) 769 (15.4) 311 (14.2) 286 (13.1)
Widowed 214 (19.9) 247 (18.5) 461 (19.1) 1,223 (24.5) 449 (20.5) 487 (22.2)
Unknown 0 (0.0) 3 (0.2) 3 (0.1) 13 (0.3) 3 (0.1) 3 (0.1)
Preadmission diseases
Myocardial infarction 77 (7.2) 134 (10.0) 211 (8.8) 552 (11.1) 210 (9.6) 206 (9.4)
Heart failure 91 (8.5) 142 (10.6) 233 (9.7) 760 (15.2) 228 (10.4) 250 (11.4)
Peripheral vascular disease 87 (8.1) 144 (10.8) 231 (9.6) 679 (13.6) 230 (10.5) 218 (10.0)
Cerebrovascular disease 117 (10.9) 129 (9.7) 246 (10.2) 748 (15.0) 241 (11.0) 235 (10.7)
Chronic pulmonary disease 29 (2.7) 71 (5.3) 100 (4.2) 667 (13.4) 100 (4.6) 96 (4.4)
Liver disease 22 (2.1) 18 (1.4) 40 (1.7) 211 (4.2) 40 (1.8) 43 (2.0)
Moderate to severe renal disease 18 (1.7) 38 (2.9) 56 (2.3) 517 (10.4) 56 (2.6) 52 (2.4)
Cancer 140 (13.1) 149 (11.2) 289 (12.0) 695 (13.9) 277 (12.6) 269 (12.3)
Metastatic cancer 22 (2.1) 27 (2.0) 49 (2.0) 85 (1.7) 42 (1.9) 45 (2.1)
Diabetic retinopathy 44 (4.1) 142 (10.6) 186 (7.7) 452 (9.1) 182 (8.3) 167 (7.6)
Diabetic nephropathy 13 (1.2) 50 (3.8) 63 (2.6) 370 (7.4) 63 (2.9) 63 (2.9)
Hypertension 389 (36.3) 488 (36.6) 877 (36.4) 1,804 (36.1) 795 (36.3) 798 (36.4)
Clinical obesity 126 (11.7) 188 (14.1) 314 (13.0) 454 (9.1) 261 (11.9) 259 (11.8)
Alcoholism 47 (4.4) 40 (3.0) 87 (3.6) 403 (8.1) 87 (4.0) 100 (4.6)
Diabetes duration > 5 years 334 (31.1) 939 (70.3) 1,273 (52.9) 2,440 (48.8) 1,122 (51.2) 1,149 (52.4)
HbA1c levela
< 6.50% 329 (30.7) 222 (16.6) 551 (22.9) 1,027 (20.6) 484 (22.1) 488 (22.3)
6.50% to 6.99% 214 (19.9) 168 (12.6) 382 (15.9) 1,014 (20.3) 379 (17.3) 350 (16.0)
7.00% to 7.99% 230 (21.4) 342 (25.6) 572 (23.8) 888 (17.8) 481 (21.9) 492 (22.5)
≥ 8.00% 112 (10.4) 374 (28.0) 486 (20.2) 888 (17.8) 436 (19.9) 458 (20.9)
Missing 188 (17.5) 229 (17.2) 417 (17.3) 1,179 (23.6) 412 (18.8) 404 (18.4)
Concurrent drug use
Low-dose aspirin 447 (41.7) 563 (42.2) 1,010 (41.9) 1,735 (34.7) 874 (39.9) 896 (40.9)
Beta-blockers 417 (38.9) 554 (41.5) 971 (40.3) 1,888 (37.8) 878 (40.1) 895 (40.8)
Statins 674 (62.8) 898 (67.3) 1,572 (65.3) 2,203 (44.1) 1,354 (61.9) 1,387 (63.3)
aLast HbA1c measurement within a year before admission. Not available for the entire study area and period; n, number of patients.
Christiansen et al. Critical Care 2013, 17:R192 Page 4 of 11
http://ccforum.com/content/17/5/R192
Christiansen et al. Critical Care 2013, 17:R192 Page 5 of 11
http://ccforum.com/content/17/5/R192glucose levels (HbA1c greater than 8%) within a year
before admission were more common in metformin
combination therapy users and less common in metformin
monotherapy users, compared to non-users. Cardiovascular
drugs, particularly statins, were more frequently prescribed
to metformin users than to non-users (Table 1).
There was little difference in the primary diagnosis
recorded for the current hospitalization, except for a
larger proportion of metformin users admitted because of
cardiovascular disease and a smaller proportion admitted
with infectious disease compared with non-users (Table 2).
Thirty-six percent of metformin monotherapy users and
38% of metformin combination therapy users had a
non-surgical reason for ICU admission, compared to 42%
of non-users. Admission after cardiac surgery was more
frequent in metformin users (Table 2). Ten metformin
users (0.4%) and no non-users had a primary diagnosis of
lactic acidosis.
Organ dysfunction, organ supportive treatment, and
inflammation
Renal, liver, and coagulation dysfunction on the day of
ICU admission, as evidenced by increased creatinine
levels, increased bilirubin levels, and decreased platelet
counts, were less common in both metformin monotherapy
users and metformin combination therapy users, compared
with non-users. However, the difference in renal dysfunc-
tion was less pronounced after propensity-score matching
based on the other covariates (Table 2).
Metformin users were more frequently treated with
mechanical ventilation than non-users (47% versus 39%),
but there was virtually no difference in use of inotropes/
vasopressors and renal replacement therapy (Table 2).
When comparing the propensity score-matched cohorts,
intensive care treatments were only slightly more common
among metformin users (Table 2).
The median CRP at day of ICU admission was lower
in metformin users compared with non-users, both in
the full cohort (107 mg/L versus 179 mg/L) and in the
propensity score-matched cohort (108 mg/L versus 157
mg/L) (Table 2).
Mortality
Mortality data are presented in Table 3. Thirty-day
mortality was 17.6% in metformin monotherapy users,
17.9% in metformin combination therapy users, and 25.0%
in non-users. There were no major mortality differences
between non-users who did not receive anti-diabetic drugs
and users of sulfonylurea, insulin, or other/combination
therapies (Table 3).
The mortality rate in metformin users was decreased
in both monotherapy (adjusted HR (aHR) = 0.80, 95% CI
0.69, 0.94) and combination therapy users (aHR = 0.83,
95% CI 0.71, 0.95) compared to non-users, after adjustmentfor age, sex, marital status, diabetes duration, preadmission
HbA1c level, preadmission morbidity, and concurrent
cardiovascular medication (Table 3). Although adjustment
for organ dysfunction upon ICU admission may attenuate
the estimate with regard to any effect mediated through
organ dysfunction, this had little influence on the combined
estimate for metformin use in the portion of the cohort
for whom we had these data (aHR including organ dysfunc-
tion = 0.88, 95% CI 0.77, 1.00 compared to aHR = 0.85,
95% CI: 0.75-0.97). The propensity score-adjusted analysis
also provided virtually the same estimates as the overall
analysis (Table 3).
In the propensity score-matched cohorts, 30-day
mortality was 18.2% in metformin users and 20.9% in
non-users, corresponding to an unadjusted HR of 0.87
(95% CI 0.76, 1.00). As expected, further adjustment
for the variables originally included in the propensity score
did not change the estimate (Table 3).
Among all 7,404 patients, 2,408 (32.5%) were current,
476 (6.4%) were recent, 591 (8.0%) were former, and
3,929 (53.1%) were never-users of metformin. Compared
to never-use, current use was associated with a decreased
mortality rate (aHR = 0.82, 95% CI 0.72, 0.92), whereas
there was no clear association with recent use (aHR = 0.92,
95% CI 0.75, 1.13) and former use (aHR = 1.08, 95% CI
0.90, 1.28). Among current users, 146 were new users and
2,262 were long-term users. The decrease in mortality was
similar, but imprecise, in new users (aHR = 0.76, 95% CI
0.51, 1.15) compared with long-term users (aHR = 0.82,
95% CI 0.73, 0.93).
Comparison of metformin monotherapy users (n = 1,073)
with sulfonylurea monotherapy users (n = 872) showed a
less pronounced association, with an aHR of 0.90 (95% CI
0.73, 1.11), but with an aHR of 0.77 (95% CI 0.63, 0.94) in
the propensity score-adjusted analysis (Table 3).
Changing the anti-diabetic drug capture window from
90 to 180 or 365 days before ICU admission slightly
increased the number of metformin users, but did not
change the estimates considerably.
Data on inpatient medication use between hospital
admission and ICU admission were available for 994
patients, including 318 preadmission metformin users and
676 metformin non-users. Among metformin users, 163
(51.3%) continued metformin upon hospitalization.
The adjusted HR comparing preadmission metformin
users with non-users was 0.25 (95% CI 0.13, 0.50) among
patients who received metformin during hospitalization
and 0.67 (95% CI 0.44, 1.01) among those who did not.
Stratified analyses
Figure 1 illustrates the results of the stratified analyses.
They confirm decreased mortality among metformin users
across most subgroups of ICU patients, although the
estimates were imprecise in several subgroups.
Table 2 Characteristics of current hospitalization among metformin users and non-users (overall and after
propensity- score matching)
Full cohort of all ICU patients with type 2
diabetes (n = 7,404)
Propensity score-matched
cohort














Pneumonia 28 (2.6) 45 (3.4) 73 (3.0) 211 (4.2) 65 (3.0) 89 (4.1)
Septicemia 39 (3.6) 34 (2.6) 73 (3.0) 182 (3.6) 68 (3.1) 83 (3.8)
Other infectious diseases 54 (5.0) 73 (5.5) 127 (5.3) 310 (6.2) 118 (5.4) 122 (5.6)
Diabetes 11 (1.0) 33 (2.5) 44 (1.8) 170 (3.4) 42 (1.9) 59 (2.7)
Endocrinology excluding diabetes 18 (1.7) 31 (2.3) 49 (2.0) 84 (1.7) 48 (2.2) 41 (1.9)
Cardiovascular diseases 353 (32.9) 499 (37.4) 852 (35.4) 1,407 (28.2) 764 (34.9) 723 (33.0)
Respiratory diseases 75 (7.0) 107 (8.0) 182 (7.6) 357 (7.2) 164 (7.5) 156 (7.1)
Gastrointestinal and liver diseases 119 (11.1) 129 (9.7) 248 (10.3) 624 (12.5) 226 (10.3) 230 (10.5)
Cancer and other neoplasms 133 (12.4) 129 (9.7) 262 (10.9) 566 (11.3) 243 (11.1) 256 (11.7)
Trauma and poisoning 114 (10.6) 104 (7.8) 218 (9.1) 415 (8.3) 193 (8.8) 160 (7.3)
Other 129 (12.0) 151 (11.3) 280 (11.6) 670 (13.4) 261 (11.9) 273 (12.5)
ICU admission type
Medical 391 (36.4) 502 (37.6) 893 (37.1) 2,090 (41.8) 829 (37.8) 853 (38.9)
Acute, non-cardiac surgery 288 (26.8) 332 (24.9) 620 (25.8) 1,476 (29.5) 568 (25.9) 592 (27.0)
Acute, cardiac surgery 43 (4.0) 52 (3.9) 95 (4.0) 174 (3.5) 86 (3.9) 88 (4.0)
Elective, non-cardiac surgery 164 (15.3) 192 (14.4) 356 (14.8) 673 (13.5) 324 (14.8) 303 (13.8)
Elective, cardiac surgery 187 (17.4) 257 (19.3) 444 (18.4) 583 (11.7) 385 (17.6) 356 (16.2)
Biochemical evidence of organ dysfunctiona
Renal
Creatinine <110 μmol/L 624 (58.2) 747 (56.0) 1,371 (56.9) 2,340 (46.8) 1,222 (55.8) 1,146 (52.3)
Creatinine 110 to 299 μmol/L 222 (20.7) 310 (23.2) 532 (22.1) 1,408 (28.2) 488 (22.3) 601 (27.4)
Creatinine ≥300 μmol/L 53 (4.9) 65 (4.9) 118 (4.9) 379 (7.6) 108 (4.9) 114 (5.2)
Creatinine missingb 174 (16.2) 213 (16.0) 387 (16.1) 869 (17.4) 374 (17.1) 331 (15.1)
Liver
Bilirubin <20 μmol/L 468 (43.6) 575 (43.1) 1,043 (43.4) 2,086 (41.8) 950 (43.3) 900 (41.1)
Bilirubin 20 to 101 μmol/L 65 (6.1) 81 (6.1) 146 (6.1) 446 (8.9) 130 (5.9) 175 (8.0)
Bilirubin ≥102 μmol/L 4 (0.4) 11 (0.8) 15 (0.6) 47 (0.9) 13 (0.6) 21 (1.0)
Bilirubin missingb 536 (50.0) 668 (50.0) 1,204 (50.0) 2,417 (48.4) 1,099 (50.1) 1,096 (50.0)
Coagulation
Platelet count ≥150 ×109/L 697 (65.0) 888 (66.5) 1,585 (65.8) 2,956 (59.2) 1,439 (65.7) 1,334 (60.9)
Platelet count 50 to 149 ×109/L 187 (17.4) 228 (17.1) 415 (17.2) 938 (18.8) 366 (16.7) 443 (20.2)
Platelet count <50 ×109/L 12 (1.1) 10 (0.8) 22 (0.9) 80 (1.6) 21 (1.0) 30 (1.4)
Platelet count missingb 177 (16.5) 209 (15.7) 386 (16.0) 1,022 (20.5) 366 (16.7) 385 (17.6)
C-reactive proteina-median mg/L (IQR) 103 (22-282) 112 (24-287) 107 (23-284) 179 (43-365) 108 (24-284) 157 (30-350)
ICU treatments
Mechanical ventilation 492 (45.9) 647 (48.5) 1,139 (47.3) 1,962 (39.3) 1,017 (46.4) 957 (43.7)
Renal replacement therapy 66 (6.2) 83 (6.2) 149 (6.2) 319 (6.4) 134 (6.1) 113 (5.2)
Treatment with inotropes/vasopressors 361 (33.6) 456 (34.2) 817 (33.9) 1,566 (31.4) 755 (34.4) 715 (32.6)
Results presented as number of patients (%) unless otherwise stated. aLaboratory data on day of ICU admission. bMissing data include both unmeasured and unavailable results.
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Table 3 Thirty-day mortality and hazard ratios for metformin users and non-users among type 2 diabetic patients










Metformin users 2,408 17.7 (16.3-19.3) 0.68 (0.61-0.75) 0.82 (0.73-0.91) 0.84 (0.75-0.94)
Metformin monotherapy 1,073 17.6 (15.4-20.0) 0.67 (0.57-0.78) 0.80 (0.69-0.94) 0.82 (0.70-0.95)
Metformin combination therapy 1,335 17.9 (15.9-20.0) 0.68 (0.59-0.78) 0.83 (0.71-0.95) 0.86 (0.75-1.00)
Metformin non-user 4,996 25.0 (23.9-26.3) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
- Sulfonylurea monotherapy 872 25.5 (22.7-28.5) NA NA NA
- Insulin monotherapy 1,337 25.2 (22.9-27.6) NA NA NA
- Other/combination 239 26.4 (21.3-32.5) NA NA NA
- No pharmacotherapy 2,548 24.7 (23.1-26.4) NA NA NA
Subcohort with laboratory data 5,474
Metformin users 1,799 18.0 (16.3-19.9) 0.71 (0.62-0.80) 0.85 (0.75-0.97) 0.88 (0.77-1.01)
Metformin users, adjusted for admission
organ dysfunction
1,799 18.0 (16.3-19.9) 0.71 (0.62-0.80) 0.88 (0.77-1.00) NA
Metformin non-users 3,675 24.4 (23.1, 25.8) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Propensity score-matched cohort
Metformin users 2,192 18.2 (16.7-19.9) 0.87 (0.76-1.00) 0.88 (0.75-1.02) 0.85 (0.73-1.00)
Metformin non-users 2,192 20.9 (19.3-22.7) 1.00 (Ref.) 1.00 (Ref.) 1.00 (ref.)
Monotherapy comparison 1,945
Metformin monotherapy 1,073 17.6 (15.4-20.0) 0.65 (0.54-0.79) 0.90 (0.73-1.11) 0.77 (0.63-0.94)
Sulfonylurea monotherapy 872 25.5 (22.7-28.5) 1.00 (Ref.) 1.00 (Ref.) 1.00 (ref.)
aAdjusted for all variables in Table 1. HR, hazard ratio; ref., reference; NA, non applicable.
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mortality was most pronounced in patients aged 60 years
or more and in male patients. There were no major differ-
ences between patients with or without history of kidney
or pulmonary disease, but the association was stronger in
patients without a hospital diagnosis of obesity. The asso-
ciation may be more pronounced in patients using insulin
or statins, which may also have immuno-modulating ef-
fects. Chronic hyperglycemia also may modulate the as-
sociation, as the impact of metformin was less evident
in patients with high HbA1c levels.
The potential protective effect of metformin was very
similar in medical and surgical ICU patients, except for
a small number of patients admitted after acute cardiac
surgery. The impact of metformin use on mortality was
more pronounced among patients admitted to the ICU
on the day of hospital admission, compared to patients
admitted the day after hospital admission. The lowered
mortality in metformin users was most evident in those
with a primary diagnosis of septicemia and other infectious
diseases and in patients with cancer, including patients
admitted with complications following cancer surgery
(Figure 1).Discussion
This is the first study to address the association between
preadmission metformin use and mortality after ICU ad-
mission. We found that users of metformin as monother-
apy and in combination with other anti-diabetic drugs had
decreased 30-day mortality compared to non-users. The
association persisted after adjustment for preadmission
morbidity and other potential confounders. Results were
very similar in a propensity score-matched analysis,
although the estimates were imprecise, probably because
of the smaller sample size. Importantly, former use of
metformin was not associated with decreased mortality.
Earlier data are very limited on metformin use and
outcome of critical illness. A US cohort study of 1,284
predominantly elective cardiac surgery patients included
443 preadmission metformin users and 443 non-users in
a propensity score-matched analysis. Metformin users had
fewer postoperative complications, including infections
(0.7% in metformin users versus 3.2% in non-users). In-
hospital mortality was as low as 0.7% in metformin users
compared with 1.4% in non-users (odds ratio = 0.5; 95%
CI 0.1, 2.0) [13]. An Iranian randomized trial of 21 pa-
tients with systemic inflammatory response syndrome and
Figure 1 Hazard ratios (HRs) of death within 30 days in metformin users compared with non-users. Adjusted by propensity score and
stratified according to subgroups of type 2 diabetes patients admitted to ICUs in Northern Denmark.
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treatment in the ICU and found a non-significant decrease
in pro-inflammatory cytokines on day 7 and a reduced in-
sulin requirement when metformin was added to intensive
insulin therapy [12]. This is supported by our finding of
a lower CRP level upon admission in metformin users
compared with non-users, although interpretation of their
study results was hampered by the small study population,
the exclusion of six patients after randomization, and by a
lack of data on clinical outcomes.
Our study also supports findings from experimental
animal studies that found metformin treatment to beassociated with decreased mortality in lipopolysaccharide-
induced acute lung injury or endotoxemia [9,11]. These
effects were mediated through attenuation of the pro-
inflammatory response, including a decrease in pro-
inflammatory cytokines, such as TNF-α and IL-1β, and
decreased neutrophil activation through mitochondrial
inhibition [9,11]. The hyper-inflammatory response is
a central feature of pathogenesis in the early phase of
sepsis and organ dysfunction [17], and early metformin
treatment may modulate this response beneficially. Beside
anti-inflammatory effects, the pleiotropic properties of
metformin include fibrinolytic effects that may prevent
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minogen activator [10]. We did not have clinical data to
support previous animal studies that indicated a lower rate
of acute lung injury [11]. In fact, we found an increased rate
of mechanical ventilation in metformin users compared
with non-users, but this may be explained by more metfor-
min users being admitted after cardiac surgery.
Any effect of preadmission metformin use in our study
most likely resulted from mediation of the early response to
critical illness, because metformin is frequently switched to
insulin upon hospital admission. This is supported by our
finding of a more pronounced impact of metformin in
patients who continued metformin during hospitalization
and in patients admitted to the ICU on the day of
hospitalization, as these patients most likely received their
usual anti-diabetic drugs during the early phase of critical
illness. Interestingly, we found the most pronounced effect
in patients with well-controlled diabetes with a low HbA1c
level, suggesting a potential interaction with preadmission
glucose control or associated lifestyle factors.
Several issues should be considered in interpreting our
data. We had accurate data on ICU admissions, prescrip-
tion data, and death during follow up, which minimizes
information bias and selection bias. We used prescriptions
for anti-diabetic drugs as a proxy for current use, but any
non-adherence would most likely bias our estimates
towards no association. We also included patients not
receiving any anti-diabetic drugs in the comparison
group of non-users. This is unlikely to bias our results,
as we found virtually the same mortality in this group
as in other non-users, probably because this group
comprised a mix of mild and non-compliant diabetes
patients. While we had data on routine biochemical
parameters in most patients, we lacked detailed clinical
data on cardiovascular, respiratory, and cerebral dysfunc-
tion as well as urine output needed to compute the entire
SOFA score or similar severity of illness scores. Still, the
SOFA score upon admission may reflect chronic as well
as acute organ dysfunction.
More metformin users than non-users were admitted
after surgery; however, we found a potential beneficial
effect in both medical and surgical ICU patients. Although
we did not include data to assess the incidence of ICU
admission in metformin users and non-users, we do not
believe that there is any major difference as the prevalence
of metformin use was very similar in our study compared
with the prevalence in type 2 diabetics included in a
population-based survey in 2006 [43]. Metformin is
contraindicated in patients with severe congestive heart
failure or with severe liver or renal disease, and should be
used with caution in patients aged 80 years or older and
in patients with chronic obstructive pulmonary disease
[1,44,45]. We adjusted for age and diagnosed lifestyle-
related conditions, such as chronic pulmonary disease,obesity, alcohol-related disease, and cardiovascular disease.
Unmeasured confounding from lifestyle factors is unlikely
to have a major impact on our findings because there
may be no major differences in smoking, diet, and physical
activity between users of various anti-diabetic drugs in
Denmark [43]. However, obesity is more frequent in
metformin users and may be associated with reduced
mortality in ICU patients [46,47]. Results were similar for
stratified analyses of patients without chronic pulmonary
disease or without a diagnosis of obesity. Additionally,
a true drug effect was supported by the fact that the
decreased mortality was restricted to current metformin
users. No association was found in former users, who are
expected to be very similar with regard to the indication
for prescribed metformin.
Although ICU patients may benefit from preadmission
use of metformin, the effects and safety of metformin
treatment initiation and continuation in patients who are
already critically ill remain to be further clarified. Treatment
with metformin generally is not recommended during
hospitalization because of the potential risk of lactic acid-
osis reported in patients with severe kidney, liver, or heart
disease, in patients recovering from major surgery, and in
patients with shock [1,45,48]. However, we found few
metformin users with a diagnosis of lactic acidosis, and
the risk of this condition in metformin users may be
overestimated [49]. The potential risk of lactic acidosis
should be balanced against the possible benefits of
metformin, and further studies are needed to assess
whether routine discontinuation of metformin upon
hospitalization is warranted.
In our study the non-randomized allocation of metformin
treatment may have given rise to uncontrolled confounding
by indication for metformin treatment, but altogether our
analyses support a potential causal association between
preadmission metformin use and decreased mortality.
We conducted the study in a homogenous population
with equal access to health care including prescription
medication, which strengthened the validity of our findings.
However, these findings might not be generalizable directly
to other more heterogeneous health care systems.
Conclusions
Preadmission metformin use was associated with reduced
30-day mortality among medical and surgical intensive
care patients with type 2 diabetes.
Key messages
 Metformin has anti-inflammatory and anti-
thrombotic effects that may influence the outcome
of critical illness, but clinical data are limited.
 We found that ICU patients who were prescribed
metformin within 90 days before admission have
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patients who were not preseribed metformin.
Former use of metformin was not associated with
decreased mortality.
 The decreased mortality was evident after
adjustment for preadmission morbidity and other
potential confounders and results were confirmed in
a propensity score-matched analysis.
 The decreased mortality was found across most
subgroups of ICU patients.
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